You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
銀河聯昌:上調三生製藥(1530.HK)目標價47%至13港元
格隆匯 05-28 13:26

銀河聯昌發表研究報告指出,三生製藥(1530.HK)高級管理人員的變動以及益賽普產品的增長壓力,或已在歷史低位的估值中得到反映,近期的股東增持等將提供關鍵催化,上調公司目標價47%至13港元。

報告指出,因公司益賽普產品的競爭產品價格下調和新冠疫情的影響,預計公司今年收入將下滑15%,但將會在2021和2022年恢復10%的增長,主要因患者增加、高於競爭對手的市場營銷能力等因素,特比澳(TPIAO)依然是公司最重要的驅動力,預計2020-2022年該產品收入將分別成長18%、27%和25%。

報告説,除了股東增持外,催化因素還包括今年新藥品的發佈、分拆三生國建到科創板上市等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account